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Abstract
The hypoxic microenvironment contributes to embryonic development and tumor progression through stabilization of the
potent transcriptional factor HIFa. In normoxia, the tumor suppressor protein VHL acts as an E3 ubiquitin ligase to target
HIFa for proteolytic destruction. Increasing evidence shows that VHL is a multifunctional adaptor involved in inhibition of
HIFa-dependent and independent cellular processes. However, the molecular effect of hypoxic stress on VHL functions
remains elusive. Here we report that PIASy, a SUMO E3 ligase upregulated in hypoxia, interacts with VHL and induces VHL
SUMOylation on lysine residue 171. Moreover, PIASy-mediated SUMO1 modification induces VHL oligomerization and
abrogates its inhibitory function on tumor cell growth, migration and clonogenicity. Knockdown of PIASy by small
interfering RNA leads to reduction of VHL oligomerization and increases HIF1a degradation. These findings reveal a unique
molecular strategy for inactivation of VHL under hypoxic stress.
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Introduction
The ability of cells to recognize and respond to a low-oxygen
environment (hypoxia) is critical in many physiological and
pathological conditions [1,2]. All mammalian cells express
components of a conserved hypoxia response pathway [3]. The
transcriptional factor HIF (hypoxia-inducible factor) is a central
regulator of this pathway. HIF is a heterodimer that consists of an
inducible a subunit and a constitutively expressed b subunit (also
known as ARNT) [3]. To date, at least three HIFa (HIF1a,
HIF2a, and HIF3a) have been identified that regulate transcrip-
tional programs in response to low oxygen levels. Under normal
oxygen tension, HIF1a is hydroxylated and rapidly targeted for
proteasome-mediated degradation through the ECV (or VBC,
namely elongin BC/Cul2/VHL) E3 ubiquitin ligase complex
which requires the recognition of von Hippel Lindau (VHL) tumor
suppressor [4–6]. When cells are exposed to a hypoxic
environment, this hydroxylation-mediated degradation pathway
is blocked, thereby allowing HIF1a to accumulate in the nucleus,
where it binds to the constitutively expressed HIF1b and
transactivates hypoxia-responsive genes that are implicated in
cellular metabolism, angiogenesis, invasion, and metastasis [3,7].
However, other studies suggest that VHL is also able to target
HIF1a for destruction in an hydroxylation independent manner
during hypoxia [8]. These studies indicated that VHL is a critical
regulator of the ubiquitous oxygen-sensing pathway.
VHL was first identified as a tumor suppressor in 1993 [9].
Inactivation or loss of both VHL alleles has been widely demonstrat-
ed in the majority of sporadic clear cell renal carcinomas and
cerebellar hemangioblastomas [10]. Reintroduction of wild type VHL
into VHL
2/2 renal carcinoma cells (RCC) suppresses tumor
formation in vivo [11]. In humans, the VHL gene encodes a 213-
residue protein which contains two functional domains but neither
with any known enzymatic activity [12]. The a domain binds to
elongin C and the b domain acts as the substrate-docking interface for
targeting proteins [13]. The best-characterized function of VHL is as
an adaptor for targeting HIFa for proteolytic degradation [5,6], and
has been considered to be the major tumor suppressor activity
associated with VHL. Nevertheless, although many of the HIFa-
induced cellular responses undoubtedly contribute to tumor progres-
sion, alone they appear to be insufficient to induce tumor formation
[12]. Notably, recent studies have demonstrated that VHL also
negatively regulates several HIFa-independent transcriptional path-
ways, which includes targeting Rbp1 (the large subunit of the RNA
polymerase II complex) for ubiquitylation in a similar manner to
HIFa [14]; linking CKII kinase with CARD9 for inhibition of NF-kB
pathway [15]; and stabilizing Jade-1 for proteasomal degradation of
oncoprotein b-catenin [16]. These imply that VHL is a multipurpose
adaptor protein that engages in multiple protein-protein interactions
to control diverse HIFa-dependent and independent cellular
processes. Thus, under hypoxic stress, inactivation or loss of VHL
function appears to be an early and requisite step in tumor
development. Exploring the regulatory mechanisms underlying
VHL cellular functions in oxygen-deprived cells is likely to also be
important.
The protein inhibitors of activated STAT (PIAS) proteins were
originally reported as specific inhibitors of the STAT family of
transcription factors [17], and more recently they have been
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There are at least five mammalian PIAS proteins that have been
identified so far, PIAS1, PIAS3, PIASx (a/b), and PIASy [18].
They all contain a conserved RING finger-like domain and have
SUMO E3 ligase activity with differing target specificities [19,20].
Similar to ubiquitin-like modification, PIAS-mediated SUMOyla-
tion is also reversible and dynamic and regulates diverse cellular
processes, including protein targeting, stabilization, nuclear
translocation, transcriptional control and stress response
[18,21,22].
Here we identify PIASy as a specific negative regulator of VHL
in response to hypoxic stress. We show that PIASy interacts with
VHL and induces VHL SUMOylation on lysine 171, facilitating
its oligomerization. This results in inactivation of the inhibitory
function of VHL as a tumor suppressor via both HIF-dependent
and independent ways.
Results
Lys-171 is the primary site for SUMO modification of VHL
Increasing evidence shows that SUMO1 modification is
involved in regulation of HIF signaling pathway during hypoxia
[8,23], we wanted to determine whether VHL undergoes SUMO1
posttranslational modification. Analysis of the human VHL
protein sequence indicated the presence of a VK171PE motif in
the alpha domain that fits the conserved motif (yKXD/E) for
SUMO conjugation (Figure 1A) [24]. Furthermore, this motif and
the adjacent residues are completely conserved in all VHL
proteins from different species, including humans, monkey, dog,
rat and mice (supplementary information, Figure S1). To
determine whether lysine 171 residue is required for the
SUMOylation of VHL, we performed an in vitro SUMOylation
assay with wild type VHL and a mutant where the lysine at
position 171 was replaced by arginine using site directed
mutagenesis.
35S-labeled VHL proteins were incubated with
Aos1/Uba2 (E1), Ubc9 (E2), SUMO1, and ATP which resulted
in detectable SUMOylation of wt VHL but not of the K171R
mutant (Figure 1B), suggesting that Lys-171 is the major
SUMOylation site on VHL. To confirm that VHL is SUMO
modified in vivo, we individually immunoprecipitated SUMO1
from native and denatured cell lysates of VHL positive or negative
786-O and analyzed the samples by immunoblotting with the
specific antibody against VHL. Surprisingly, of the two major
VHL-antibody-reacting bands (,80 and 24 kDa; Figure 1C, top
panel, lane 1 to 3) in VHL positive cells under native condition,
and only the 80 kDa protein band (suVHL-L) but not a band with
in vitro suVHL size was recognized by the VHL antibody under
denaturing conditions (Figure 1C, bottom panel, lane 1 to 3).
These data demonstrate that endogenous VHL with an apparent
molecular weight of 80 kDa is conjugated with SUMO1, and that
native VHL associates with SUMO1-modified VHL or other
proteins with SUMO1 modification. The observation that
SuVHL-L complex levels of native VHL are increased by
treatment with the deSUMOylation inhibitor (NEM) further
supports this conclusion, although it was not a dramatic increase
when NEM was increased.
PIASy interacts with VHL and induces VHL SUMOylation
To explore the reason for the different size of VHL
SUMOylation in vitro and in vivo, we next sought to identify
whether a specific SUMO E3 ligase was involved in the process of
VHL SUMOylation. Since the members of PIAS family are the
major SUMO E3 ligases [18], we performed coimmunoprecipita-
tion assays to determine whether VHL associates with one of the
PIAS family members in vivo. Strikingly, we observed that only
PIASy but not any other member (PIAS1, PIAS3, and PIASx) of
the PIAS family strongly associated with VHL by coimmunopre-
cipitation assays (Figure 2A). The data from the immunoprecip-
itation assays targeting VHL, followed by immunoblotting for
PIASy, showed that endogenous VHL indeed immunoprecipitated
with PIASy (Figure 2B). To determine whether PIASy contributes
to VHL SUMOylation, we performed in vitro SUMOylation assays
Figure 1. VHL can be SUMOylated in vitro and in vivo. (A)
Schematic representation of VHL with three potentially modification
Lysines K159, K171 and K196. K171 is the putative SUMOylation site
based on SUMOplot
TM analysis. Su, SUMO. (B) Wild type VHL but not
its K171R mutant was SUMOylated by SUMO1 in vitro. In vitro-
translated, radiolabeled VHL was incubated with the indicated
recombinant proteins. Reaction mixtures were analyzed by SDS-PAGE
and autoradiography. (C) SUMO1 modification of endogenous VHL.
HEK293 and 786-O cells were individually treated with deSUMOylation
inhibitor NEM (20 mM, 40 mM) for 1 hour before harvest. Cell lysates
were subjected to native or denature immunoprecipitation with
antibodies against SUMO1 (Y299), and immunoblot analysis with
antibodies against VHL. The membranes were stripped and reblotted
with SUMO1 antibodies. SuVHL, SUMOylated VHL; HC, heavy chain; LC,
light chain.
doi:10.1371/journal.pone.0009720.g001
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showed that PIASy does increase the intensity of ,43 kDa
SUMO1-conjugation band of VHL in vitro (Figure 2C). Further
experiments using coimmunoprecipitation assays showed that
PIASy was able to enhance the affinity of SUMO conjugating
enzyme Ubc9 bound to VHL (data not shown). Unexpectedly, in
the coexpression system, the results of immunoprecipitation
followed by immunoblotting showed that neither PIASy nor
SUMO1 alone induces the ,43 kDa band of SUMOylated VHL,
but a migrating band which is similar in size to endogenous
SUMOylated VHL (SuVHL-L) (Figure 2D, lane 3 and 4,
compared with Figure 1C, lane 1 to 3). Moreover, in contrast to
either PIASy or SUMO1 alone, the combination of both PIASy
and SUMO1 further increased the intensity of SuVHL-L
(Figure 2D, lane 5 compared with lane 3, 4). The site mutation
of RING domain of PIASy resulted in the loss of PIASy activity on
SuVHL-L (Figure 2D, lane 3 and 6), and thus indicated that the
SUMO E3 ligase function of PIASy is required for PIASy-induced
SUMOylation of VHL. Previous studies have reported that PIASy
can interact with p53 [25], and that p53 can associate with VHL
[26]. To exclude the possibility that p53 might be contributing to
VHL SUMOylation, we also tested p53 deficient Saos-2 cells.
Interestingly, PIASy does induce SuVHL-L in the Saos-2 cells and
argues against p53 as a linker for PIASy and VHL interaction
(data not shown). Furthermore, although PIASy bound equally to
wild type VHL and its K171R mutant, PIASy only induced
SuVHL-L band in wild type VHL instead of the K171R mutant
(Figure 2E), indicating that SuVHL-L is indeed an isoform of
VHL SUMOylated on Lys-171.
PIASy-mediated SUMOylation of VHL facilitates
oligomerization
As the molecular mass of SuVHL-L induced by PIASy is about
2 times of mono-SUMOylated VHL, we hypothesized that
SuVHL-L might be a dimer of mono-SUMOylated VHL, and
that PIASy induces VHL SUMO1 modification resulting in its
oligomerization. To directly address this point, we individually
generated VHL-SUMO1
DC4 by fusing the SUMO1 molecule to
the carboxyl terminus of VHL with Lys171 mutation (as SUMO1
modification occurs within the carboxyl terminus of VHL, and to
avoid other posttranslational modifications besides SUMOylation
on Lys171), and the C-terminal glycines in charge of the covalent
link were removed in SUMO portions to exclude the possibility of
the fusion protein acting as a SUMO-like molecule. The VHL
fusion with ubiquitin (VHL-Ub
DGG) using the same strategy was
used as a parallel control. We then detected the expression pattern
of VHL -SUMO1
DC4, VHL-Ub
DGG, as well as the wild type VHL
and its K171R or K196R mutants in 786-O cells. In agreement
with our hypothesis, the immunoblotting results from the whole
cell lysates showed that only VHL-SUMO1
DC4 and neither wild
type VHL nor its single lysine mutants (K171R or K196R) was
able to undergo oligomerization as seen by the appearance of a
dimer size band which is identical to the size of endogenous
SuVHL-L (Figure 3A). Meanwhile, oligomerization of VHL-
Figure 2. PIASy enhances SUMOylation of VHL on lysine 171. (A) PIASy interacts with VHL in vivo. HEK293 cells were cotransfected with
expression plasmids as indicated in the figure. Forty-eight hours posttransfection, cell extracts were subjected to immunoprecipitated (IP) and
immunoblotting (IB) as indicated. (B) Endogenous PIASy interacts with VHL. Preclear, normal rabbit serum. (C) PIASy enhances the conjugation of
SUMO1 to VHL. In vitro-translated, radiolabeled VHL was subjected to SUMOylated assays as described in the Figure 1b in the presence of GST or GST-
PIASy. Commassie staining shows the amounts of input GST recombinant protein. Relative intensity (RD) of SUMOylated VHL (SuVHL) is indicated. (D)
RING domain of PIASy is required for SUMOylation of VHL. (E) PIASy-induced SUMOylation of VHL band (SuVHL) in vivo is abolished by lysine 171
mutation. HEK293 cells were individually cotransfected with expression vector encoding the indicated proteins in the top panel. Forty-eight hours
posttransfection, cell extracts were subjected to immunoprecipitated (IP) and immunoblotting (IB) as indicated in the figure. WCL, whole cell lysate;
SuVHL, SUMOylated VHL; HC, heavy chain; LC, light chain. The asterisk denotes uncharacterized protein band.
doi:10.1371/journal.pone.0009720.g002
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PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9720Figure 3. PIASy-mediated SUMOylation facilitates VHL oligomerization. (A) SUMO-1 modification of VHL increases VHL oligomerization in
vivo. 786-O cells were cotransfected with expressing plasmids as indicated in the figure. At 48 hr posttransfection, cell extracts were subjected to
immunoblotting with antibodies to FLAG and b-actin, respectively. (B) PIASy enhances oligomerization of VHL-SUMO1
DC4 in 786-O cells. Cells were
cotransfected with expressing plasmids as indicated in the figure, and performed oligomer assays by similar method as described in panel A. (C)
Establishment of Lentivirus-mediated PIASy knockdown in 786-O cell lines. The GFP fluorescence shows the cells with PIASy (shPIASy) or luciferase
(shLuc) knockdown after puromycin selection. The efficiency of PIASy knockdown was determined by immunoblotting with antibodies to PIASy, and
the relative density (RD) of PIASy were showed in the right panel. Actin immunoblotting was used as the loading control. DIC, differential interference
contrast. (D) Loss of PIASy represses oligomerization of SUMOylated VHL. 786-O cell lines with or without PIASy knockdown was individually
transfected with VHL-SUMO1
DC4 and performed immunoblotting for oligomerization assays. (E) The homology of two potential oligomerization
domains (OD1 and OD2) of VHL from mice (mVHL), rat (rVHL), dog (dVHL), monkey (MVHL) and human (hVHL). The acidic domain (AD), two
conserved functional domains (a and b) and high diversity carboxyl terminus is indicated. (F) The OD1 domain of VHL is required for PIASy-induced
oligomerization. 786-O cells were cotransfected with expressing plasmids as indicated in the figure, and performed oligomer assay by similar method
as described in panel A. (G) VHL-SUMO1
DC4 associates with native VHL and induces OD1-dependent oligomerization of SUMOylated VHL. 786-O cells
were cotransfected with expressing plasmids as indicated in the figure, and performed oligomer assay by similar method as described in panel A. The
membrane of VHL-SUMO1
DC4-immunoprecipitated complex followed by immunoblotting (IB) with HA antibody was stripped and reimmunbloted
(reIB) with SUMO1 to present the SUMOylation position of native HA-VHL induced by VHL-SUMO1
DC4.( H) A model of the role of PIASy functions on
VHL oligomerization. PIASy potentially contains two VHL-binding sites and collaborates to induce VHL SUMOylation and oligomerization. HC, heavy
chain; LC, light chain; WCL, whole cell lysate.
doi:10.1371/journal.pone.0009720.g003
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DC4 was enhanced by PIASy coexpression (Figure 3B),
and reduced by lentivirus-mediated loss of endogenous PIASy
(Figure 3C, D), which highlights the role of PIASy as a critical
player in oligomerization of SUMOylated VHL. To further prove
that SUMO1 modified VHL can undergo oligomerization, we
performed cross-linking assays by using the in-vitro translated
proteins VHL, VHL-SUMO1
DC4 and VHL-Ub
DGG. Consistent
with our findings, VHL-SUMO1
DC4 showed increased oligomeri-
zation compared to wild type VHL or VHL-Ub
DGG, and the extent
of VHL-SUMO1
DC4 oligomerization was similar to the oligomer-
ization of the positive control p53 (supplementary information,
Figure S2A). Unexpectedly, in the absence of the cross linker, the
mixture of in-vitro translated VHL-SUMO1
DC4 naturally produced
the dimerized form, which had strong resistance to reduction by
mercaptoethanol at high temperatures (supplementary information,
Figure S2B), further supports our hypothesis that SUMO1
modification of VHL favors oligomerization.
VHL oligomerization is dependent on Leucine-rich
domain
In an effort to define the specific domain of VHL required for its
oligomerization, we analyzed the amino acid sequence of VHL
from different species, and noticed that there are two conserved
Leucine-rich oligomerization domains (OD1 and OD2) linearly
located at the carboxyl terminus of VHL (Figure 3E), similar to the
domain of p53 required for oligomerization [27]. Using wild type
VHL and its mutants with single (OD1) or double (OD12) deletion
of oligomerization domains, we performed oligomerization assays
in the presence of PIASy and found that deletion of the OD1
domain is sufficient to abolish oligomerization of VHL in vivo
(Figure 3F). Furthermore, the intensity of SUMO1-modified VHL
dimerization is greatly reduced when the Leucine residue is
mutated in the OD1 domain compared to the OD2 domain
(Figure3A, right panel). This indicates that SUMOylation-
mediated oligomerization of VHL is dependent on its oligomer-
ization domain. In addition, we also asked whether the SUMO-
modified isoform of VHL will facilitate native VHL SUMOylation
and oligomerization in an oligomerized domain (OD1)-dependent
manner. We coexpressed HA tagged native or OD1 deleted VHL
along with FLAG-tagged VHL-SUMO1
DC4, and performed
immunoprecipitation using FLAG antibodies. We found that
FLAG-tagged VHL-SUMO1
DC4 is not only efficiently associated
with native HA-VHL, but also induced SUMOylation and
dimerization of the HA-VHL isoform which is similar in size to
the mono SuVHL and oligomerized SuVHL-L protein, respec-
tively (Figure 3G, lane 1). This evidence was further supported by
the fact that the shorter isoform of HA-VHL with amino 53
residue deletion (D1-53) had a similar pattern (Figure 3G, lane 3).
However, the two HA-VHL mutants (DOD1 and D1-53+OD1)
lacking the oligomerization domain had little or no production of
dimerized HA-VHL or other SUMO-modified isoforms, although
VHL-SUMO1
DC4 remained associated with VHL (Figure 3G,
lane 2 and 4). This strengthens our hypothesis that SUMO
modification of VHL facilitates native VHL SUMOylation and in
turn oligomerization, and that PlASy plays a critical role on both
VHL SUMOylation and oligomerization, and might contain two
VHL-interacting sites in this process (Figure 3H).
The RING domain is critical for PIASy induction of VHL
oligomerization
To determine which domain of PIASy is responsible for binding
VHL, we generated six PIASy truncated mutants with or without
the RING domain (Figure 4A). The mutant with the RING
domain deletion (D183-415) maintained a strong affinity for VHL
similar to that of full length PIASy (Figure 4A). Further deletions
showed that the region 415 to 461 of PIASy was critical for
association with VHL, although the central region (aa 233 to 415)
showed similar binding affinity when compared to the complete
loss of binding with the mutant containing only the first 233
residues (aa 1 to 233) (Figure 4A, lane 3, 4). This indicates that
residues 415 to 461 are the critical amino acids important for
interaction of PIASy with VHL. To further determine whether
PIASy can directly bind to native, SUMO or ubiquitin modified
VHL, we carried out in vitro pull-down assays. The results showed
that both native and SUMO-modified VHL were able to bind
directly to PIASy, whereas the ubiquitin-modified VHL showed
much less affinity with PIASy (Figure 4B). Intriguingly, when
compared to the monomer, the dimerized SUMO-modified VHL
showed a significantly less capability of binding to PIASy
(Figure 4B). This suggests that PIASy binds with strong affinity
to native and SUMO-modified VHL but had little or less affinity
for the ubiquitin-modified or dimerized SUMO-modified VHL
(supporting the proposed model in Figure 3H).
To determine whether the VHL-interacting domains of PIASy
are required for stimulating VHL oligomerization, we performed
oligomerization assays by using HA-tagged VHL in the presence
of different PIASy truncated mutants which includes either VHL-
binding domain a (aa 183 to 414, RING domain), b (aa 415 to 461)
alone or both. Strikingly, the results showed that neither VHL-
binding domain a nor b alone, but the intact PIASy of both a and b
was capable of inducing VHL oligomerization (Figure 4C).
Therefore, it is noteworthy that the carboxyl terminus which
includes both VHL-interacting domains a and b were required for
PIASy induction of VHL oligomerization.
PIASy binds to the b domain of VHL
Because VHL is able to directly interact with PIASy in vitro,w e
also asked which domain of VHL is required for association with
PIASy. Based on the conserved and functional domains of VHL
seen in different species [13], we generated a series of VHL
truncated mutants fused with an HA tag (Figure 4D). Using in vitro
translated VHL proteins, we performed the GST-PIASy in vitro
pull down assays. Surprisingly, the data showed that the minimal
truncated mutant of VHL b domain (aa 54 to 120) maintained
significant binding activity with PIASy when compared with the
negative control luciferase (supplementary information, Figure S3).
Moreover, all mutants deleted for the acidic domain showed
higher binding affinity to PIASy when compared to the full length
VHL (supplementary information, Figure S3, and Figure 4B). This
suggests that the acidic domain may affect the physical binding of
VHL with PIASy in vivo. To determine the role of the acidic
domain in the context of the association of VHL with PIASy, we
performed coimmunoprecipitation followed by immunoblotting
assays by using HEK293 cells coexpressing FLAG-PIASy and the
individual VHL truncated mutants. The results showed that
although the minimal truncated mutant of VHL (54-120) can
physically interact with PIASy in vitro, there was no significant
protein of the mutant with acidic domain deletion (D1-53)
precipitated by PIASy in vivo (Figure 4D). This indicated that in
addition to residues 54 to 120, the acidic domain is also required
for interaction of PIASy with VHL in vivo (Figure 4D, bottom
panel).
PIASy is upregulated by hypoxia stress to block VHL-
mediated degradation of HIF1a
Because PIASy binds to the b domain of VHL which might
overlap with the docking site for HIFa, we wanted to determine
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PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9720whether PIASy impairs the ability of VHL bound to HIFa by
competing for binding to VHL. We coexpressed HIF1a with VHL
in the presence of PIASy in 786-O cells, and monitored the levels
of VHL in the HIF1a immunoprecipitated complex when treated
with the proteasomal inhibitor. The results showed that the ability
of VHL to bind with HIF1a was dramatically reduced in the
presence of PIASy (Figure 5A, compare lane 2 with 3). Critically,
PIASy did not associate with HIF1a (Figure 5A, lane 1).
To address whether the molecular effect of PIASy on VHL is
required for HIFa stabilization in hypoxia, we determined the
endogenous levels of both SUMOylated VHL and HIFa in 293
cells with or without PIASy repression at different time points
under low oxygen conditions. As expected, in the PIASy-repressed
cells, SUMOylated VHL (SuVHL-L) was significantly reduced
along with a simultaneous loss of HIFa accumulation during
hypoxia (Figure 5B, C), which is supported by the evidence that
loss of PIASy results in less stability of SUMO1-modified VHL
(VHL-SUMO1
DC4) under prolonged hypoxia (supplementary
information, Figure S4A). In contrast to the parallel treated group
without PIASy repression, hypoxia-induced HIF1a was clearly
detected and SUMOylated VHL (SuVHL-L) showed a dramatic
increase in hypoxia compared to normoxia, although prolonged
Figure 4. The functional domains required for PIASy and VHL interaction. (A) PIASy interacts with VHL through its carboxyl 46 amino acids.
HEK293 cells were transfected with indicated expressing plasmids and harvested at 48 hr posttransfection. Cell extracts were subjected to
immunoprecipitation (IP) and immunoblotting (IB) with antibodies as indicated. Schematic showing the binding affinity of PIASy truncated mutants
with VHL (Bottom panel). (B) PIASy strongly interacts with native and SUMOylated VHL but slightly with dimerized or ubiquitylated VHL in vitro. In
vitro-translated, radiolabeled VHL, VHL-SUMO1
DC4 and VHL-Ub
DGG was individually incubated with GST or GST-PIASy recombinant proteins. Bound
complexes were analyzed by autoradiography; Input, 10%. The relative density of binding affinity is shown in the bottom panel. (C) The carboxyl
terminus including RING domain of PIASy is required to induce VHL oligomerization. 786-O cells were transfected with indicated expressing plasmids
and then harvested at 48-hr posttransfection. Cell extracts were subjected to coimmunoprecipitated (CoIP) and immunoblotted (IB) as indicated. The
asterisk denotes uncharacterized protein band. (D) Both acidic and beta domain are necessary for VHL to interact with PIASy in vivo. 786-O cells were
transfected with indicated plasmids and then harvested at 48 hr posttransfection. Cell extracts were subjected to coimmunoprecipitated (CoIP) and
immunoblotted (IB). The schematic showing the binding affinity of VHL truncated mutants with PIASy in vivo and in vitro (Bottom panel). HC, heavy
chain; LC, light chain; WCL, whole cell lysate.
doi:10.1371/journal.pone.0009720.g004
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SUMOylated VHL (Figure 5B, C). This suggests that PIASy-
induced SUMO modification of VHL is stable within short term
(,6 hr) rather than long term (.12 hr) hypoxia exposure.
Consistent with the hypothesis that PIASy stabilizes HIFa, the
results from the luciferase reporter assays with a reporter construct
containing three copies of wild type or mutated HIFa-binding
element (wHRE, mHRE) along with small interfering RNA
against PIASy or Ubc9, showed that loss of PIASy leads to a
specific reduction in the transcriptional activity of wild type HIFa-
responsive element (supplementary information, Figure S4B).
Furthermore, we also found that the protein expression of
endogenous PIASy was upregulated about 2 to 3 fold by both
low oxygen (1%) and chemical (CoCl2)-mimetic hypoxia in VHL-
positive cell lines, but showed little or no change in VHL-negative
cell lines (Figure 5D). These results suggest that PIASy is a critical
molecule which contributes to regulation of VHL in response to
hypoxic stress.
PIASy-mediated SUMO modification of VHL abolishes its
inhibitory functions on HIF1a
To further elucidate whether PIASy-induced SUMO1 modifi-
cation of VHL results in impaired formation of VHL ubiquitin
complex, we performed coimmunoprecipitation assays to deter-
mine the binding affinity of Elongin C (the key component of VHL
ubiquitin complex for targeting HIFa to degradation) with wild
type VHL and its mutants (including VHL-SUMO1
DC4 and
VHL-Ub
DGG) in the presence or absence of PIASy in VHL-
Figure 5. PIASy expression is upregulated by hypoxia for disruption of VHL-mediated HIF1a degradation. (A) PIASy competes with
HIF1a to bind VHL. 786-O cells were transfected with expressing plasmids as indicated. Forty eight-hours posttransfection, cells were treated with
20 mM MG132 for 2 hr before harvested. Cell extracts were subjected to coimmunoprecipitated (CoIP) with anti-HIF1a and immunoblotted (IB) as
indicated in the figure. Bound proteins were detected by anti-HA and anti-HIF1a immunoblotting. The membrane was stripped and
reimmunoblotted (reIB) for anti-FLAG. Relative intensity (RD) of VHL bound to HIF1a is quantitated. (B) Establishment of Lentivirus-mediated
PIASy knockdown in 293 cell lines. The GFP fluorescence shows the cells with PIASy (shPIASy) or luciferase (shLuc) knockdown after puromycin
selection. The efficiency of PIASy knockdown was determined by immunoblotting with antibodies to PIASy, and the relative density (RD) of PIASy
were showed in the right panel. Actin immunoblotting was used as the loading control. DIC, differential interference contrast. (C) Loss of PIASy
reduces SUMOylation of VHL and in turn inhibits hypoxia-induced HIF1a. 293 cells with PIASy stable knockdown or control were cultured in 1% O2 for
0, 6, and 12 hours. Cell lysate were subjected to coimmunoprecipitation against with VHL followed by immunoblotting with SUMO1, or directly
performed immunoblotting with antibodies to VHL, HIF1a and b-actin. (D) Protein level of endogenous PIASy is upregulated in hypoxia. Cells were
treated with or without hypoxia (1% O2 or CoCl2) for 12 hours. Whole cell lysates were subjected to immunoblotting with anti-PIASy. The relative
density (RD) was calculated by the quantitation of native band of PIASy in hypoxia compared to in normoxia. Intensity of Actin was used as internal
control to normalize.
doi:10.1371/journal.pone.0009720.g005
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ubiquitin modification of VHL dramatically attenuates the ability
of VHL to bind to Elongin C (Figure 6A, left panel), whereas,
there was little or no effect on VHL with the single lysine mutation
or when coexpressed with PIASy (Figure 6A). This indicates that
posttranslational SUMO1 modification blocks the ubiquitin E3
ligase function of VHL on HIFa degradation via suppression of
the VHL interaction with Elongin C.
To further corroborate this point, we determined the effect of
wild type VHL in the presence or absence of PIASy, as well as its
modified isoform (VHL-SUMO1
DC4 and VHL-Ub
DGG) on the
transcriptional activity of HIF1a in 786-O cells by co-introducing
VEGF (a key downstream molecule regulated by HIF) promoter-
driven luciferase reporter. The results of reporter assays showed
that wild type PIASy but not their RING domain mutant (m1 and
m2) dramatically reverses the inhibition of VHL on the
transcriptional activity of HIF1a on VEGF promoter (Figure 6B).
Moreover, the transcriptional activity of HIF1a in SUMO1-
modified VHL (VHL-SUMO1
DC4) group had greatly increased as
compared with wild type VHL, although the Ubiquitin-modified
isoform (VHL-Ub
DGG) also to some extent reverses inhibition of
VHL on HIF1a (Figure 6B). This indicates that PIASy-mediated
SUMOylation of VHL abrogates its inhibitory functions on
HIF1a. Concordantly, in vitro endothelial tube formation assay
using conditioned medium from the supernatants of the VHL or
VHL/PIASy -expressing 786-O cells, showed that both PIASy
coexpression and SUMO1 modified VHL markedly reduced the
inhibitory ability of wild type VHL on tubule formation
(Figure 6C, panels c and e), instead of the RING domain mutant
of PIASy or Ubiquitin modified isoform (Figure 6C, panels d and
f). Meanwhile, the results of condition medium from the
supernatants of PIASy-repressed cells with 6 hr hypoxia treatment
showed less ability to induce tube formation (Figure 6C, middle
and bottom panels), further suggests that PIASy-mediated
SUMOylation of VHL indeed inactivates native VHL and
rescued HIFa from degradation.
The SUMO1 modification of VHL inactivates its other
HIF1a-independent tumor suppressor functions
To ascertain if SUMO modification is sufficient to inactivate
the inhibitory functions of VHL on tumor cells, we tested
Figure 6. The SUMO1-modified isoform of VHL inactivates its inhibitory ability on the transcriptional activity of HIF2a. (A) SUMO1-
modified isoform of VHL reduces its ability to associate with Elongin C. 786-O cells were transfected with expressing plasmids as indicated. Forty-
eight hours posttransfection, whole cell extracts were subjected to coimmunoprecipitated (CoIP) and immunoblotted (IB) as indicated in the figure.
(B) The effect of PIASy-mediated SUMO modification of VHL on the transcriptional level of VEGF promoter-luciferase reporter. 786-O cells were
cotransfected VEGFp-luciferase reporter (5 mg) with VHL expressing plasmids (10 mg) in the presence or absence of PIASy (w, wild type; m1, mutant
D183-414; m2, mutant C2A) as indicated. Total equal DNA amounts were made up by empty vector. The equal each protein expressions was
confirmed by immunoblotting. Data are presented as means6SD of three independent experiments. (C) PIASy- mediated SUMOylation of VHL
reverses the inhibitory effect of VHL on endothelial tube formation in vitro. The conditioned medium from 786-O cells expressing vector, wt VHL, wt
VHL and PIASy (m1, PIASy mutant D183-414,), VHL-SUMO1
DC4, or VHL-Ub
DGG, or from PIASy-knockdown (shPIASy) or luciferase (shLuc) control 293
cells with 6 hr low oxygen (1% O2) treatment, was tested for tube formation assay in vitro. Photographs were taken at 24 hr post-incubation. The
quantitation presents the average of the pattern/value association criterion from 5 random view fields per well.
doi:10.1371/journal.pone.0009720.g006
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ed in dysregulation of VHL as the cells exit the cell cycle on
serum deprivation. Similarly, 786-O cells were transfected with
vector, vector expressing wild-type VHL in the presence or
absence of PIASy (wild type or mutants), or its modified
isoform VHL-SUMO1
DC4 and VHL-Ub
DGG. In 10% serum,
no difference in DNA content was observed between vector
and wild type VHL or its modified isoforms, showing the
similar growth characteristics for all cell lines (data not shown).
However, when cells were switched to 0.1% sera for 24 hr, the
DNA content of 786-O (Vector) cells was not significantly
changed (Figure 7A, lane 1), whereas a dramatic increase in
G0 DNA content was observed with the 786-O(wt) cells
(Figure 7A, lane 2). Meanwhile, when coexpression with wt
PIASy but not its RING domain mutants, VHL showed a great
decrease in G0 DNA content, and the SUMO-modified
isoform of VHL showed the most efficient inhibition of G0
arrest induced by wt VHL, which was almost the same as
vector control (Figure 7A, lane 6 and 3 compared with lane 1).
By contrast, readdition of 10% serum did not significantly alter
the DNA content of the 786-O (vector, wt, or mutant) cells,
suggesting that PIASy-mediated SUMO modification of VHL
effectively blocked the inhibitory function of VHL on cell cycle
progression in low serum. Furthermore, analysis of endogenous
VHL levels, gene silencing of PIASy also specifically increased
G0 arrest in the VHL positive cells with low serum treatment,
but not in VHL negative cells (supplementary information,
Figure S5A), suggesting that SUMO modification not only
inactivated the control of VHL on cell cycle arrest but also
increased cell cycle progression in hypoxia. To support this
data, cell proliferation assays were performed using stably
transfected wild type VHL and its mutants in 786-O cells. The
results further showed that 786-O (VHL-SUMO1
DC4) cells
grew faster than 786-O (vector) cells, whereas 786-O (wt) cells
were dramatically slowed (Figure 7B). Unlike in normoxia,
gene silencing of PIASy consistently showed a decrease in
proliferation of VHL positive cells but not VHL negative cells in
hypoxia (Figure 7C), further corroborating the above data that
PIASy-mediated SUMOylation of VHL does affect cell cycle
progression during hypoxia.
To determine whether the inhibitory function of VHL on
cell migration is also impaired by SUMO modification, we
performed scratch wound assay to assess the effect of SUMO
modification on the inhibition of VHL on 786-O cell motility.
The results showed that the wild type VHL-expressing cells
spread along the wound edges significantly slower than vector-
transfected cells. However, the VHL-SUMO1
DC4-expressing
cells had similar motility compared to the vector-transfected
cells (Figure 7D). Concordantly, loss of PIASy suppresses the
cell migration of VHL positive cells (supplementary informa-
tion, Figure S5B), indicating that SUMO modification
abolished the inhibitory effect of VHL on tumor cell
migration. In addition, as it is known that 786-O cells devoid
of VHL grow as very compact and cohesive spheroids, while
VHL-reintroduced 786-O cells grow as loosely arranged
spheroids [28,29], we compared the 786-O cells with wild
type VHL or its mutants. The results showed that among the
wt VHL and its mutants expressing 786-O cells, multiple
SUMO-modified VHL (VHL-SUMO
DC4)–expressing 786-O
subclones grew as compact spheroids and closely resembled
786-O cells devoid of functional wt VHL (Figure 7E). Thus,
SUMO modification of VHL is necessary for tumor cell
growth in three-dimensional space mimicking the in vivo
multicellular tumor growth conditions.
Discussion
Although the ability of VHL to target HIFa for proteolysis as a
ubiquitin E3 ligase is one of its major function [5], increasing
evidence have demonstrated that VHL is a multipurpose adaptor for
involvement in the inhibition of angiogenesis, cell cycle exit and
fibronectin matrix assembly in a HIF-dependent or independent
manner [30–32]. The overexpression of HIFa alone is insufficient to
induce tumor formation in some cases [12], and genetic mutation of
VHL leads to a range of human diseases [33]. Thus, it is highly
possible that hypoxia may also inactivate VHL function as a tumor
suppressor besides stabilizing HIFa by blocking hydroxylation.
Although a great deal of effort has been put into studying the
molecular mechanism of hypoxia stress on HIFa stabilization via
posttranslational regulation [8,23,34–36], it still remains unclear
whether hypoxia affects overall VHL tumor suppressor function.
R e c e n t l y ,s o m es t u d i e sh a v es h o w nt h a ti na d d i t i o nt og e n e t i c
mutation the function of ubiquitin ligases (like VHL) can be
dysregulated by controlling the ligase activity or the substrates using
a number of strategies including posttranslational modifications,
interactions with regulatory factors, or subcellular localization [37].
In this report, we now showed that PIASy, a SUMO E3 ligase, is up-
regulated by hypoxia and stimulates VHL SUMOylation on lysine
residue 171, which facilitates VHL oligomerization and inactivates
VHL as a tumor suppressor in both a HIFa-dependent and
independent strategy (Figure 8). Despite increasing reports showing
that hypoxia induces HIF1a SUMOylation, and HIF1a stabilization
depends on the deSUMOylation enzyme SENP1 [8,38], we now
provide an additional mechanism which shows that hypoxia also
upregulates PIASy expression andi n a c t i v a t e sV H Lb yp r o m o t i n g
PIASy-mediated SUMOylation and oligomerization. This disrupts
VHL ability to target HIF1a for degradation, and suggests that the
oxygen-dependent recognition and binding of HIF1a by VHL might
be precisely timed in that PIASy affects the engagement of VHL to
either ECV E3 ubiquitin complex or other protein complex, thereby
establishing a critical role for PIASy to promote the SUMOylation
and oligomerization of VHL in a temporally coordinated manner,
thus leading to inactivation of VHL function as a tumor suppressor
in a HIFa-dependent and independent manner during hypoxia.
To date protein SUMOylation has emerged as an important
strategy for modification of many proteins that play regulatory
roles in diverse cellular processes, including protein relocalization,
stability and stress response [22]. The PIAS family of SUMO E3
ligases has two domains that are crucial for SUMOylation: the
RING finger domain that binds to Ubc9 and the SUMO-
interacting motif that binds to SUMOs [22]. The RING finger
domains of the PIAS proteins are indispensable for their SUMO
E3 ligase activity [22]. In our study, although the deletion mutant
of either RING domain or SUMO-interacting motif of PIASy
(D183-415 and 1-461) retains the ability to associate with VHL,
both of these two domains are required for PIASy-mediated in vivo
VHL SUMOylation and oligomerization (Figure 4A and C),
further supporting the notion that both RING finger and SUMO-
interacting domains are critical for targeting proteins to be SUMO
modified. More importantly, these results demonstrated that
PIASy is unique in its mode of action when compared to other
PIAS members in terms of its ability to interact with VHL and
respond to hypoxia. Our data add to the growing evidence
showing that posttranslational modifications can play a major role
in regulating the activity of VHL, and raise the possibility that
PIASy is a key regulator which responds to different cellular
environments, including genotoxic and hypoxic stress [39],
through the targeting of specific molecules (like NEMO and
VHL), respectively.
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PLoS ONE | www.plosone.org 9 March 2010 | Volume 5 | Issue 3 | e9720Figure 7. The SUMO1-modified isoform of VHL blocks its tumor suppressor function. (A) SUMO1-modified isoform of VHL eliminates the
regulation of VHL on cell cycle under serum starve condition. 786-O cells were transfected with VHL expressing plasmids in the presence or absence
of PIASy (w, wild type; m1, mutant D183-414; m2, mutant C2A) as indicated. At 24 hr posttransfection, cells were plated and incubated for 24 hrs in
0.1% serum, followed by incubation in 10% serum for 24 hrs or directly analyzed by flow cytometry after staining with propidium iodide. The relative
ratios of G0 phase in each group under serum starve condition were showed by number compared to vector only. The data presents from three
independent experiments. (B) Growth curves of 786-O cells expressing wild type VHL or its modified isoforms. The values are shown as means from
two independent experiments. (C) Effect of hypoxia on the growth of VHL positive and VHL negative expressing cell lines with or without PIASy stable
knockdown. The equal amount of each cell line was seeded. The cell numbers were counted at two days with either 21% or 1% oxygen treatment for
18 hours. a, HeLa; b, 293; c, 786-O; d, RCC4. (n=3 assays/group, *p,0.05). (D) The cell mobility of wild type VHL and its modified isoform was
determined by wound migration assay. The VHL-SUMO1
DC4-expressing cells spreading along the wound edges are significantly slower, compared
with the wild type VHL-expressing cells. All experiments were performed in triplicate. (E) SUMO1 but not ubiquitin modification of VHL affects the
growth of RCC cells in a 3D growth assay. Digital images (640) of the indicated and representative 786-O subclones grown as spheroids in semisolid
media were captured on day 3. After ten days, colonies were counted and presented in the bottom.
doi:10.1371/journal.pone.0009720.g007
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response to hypoxic stress. However, this is not a unique example
for cells in response to environment stress. In the oxidative
environment, it has been found that the membrane protein MG53
undergoes oligomerization to initiate the assembly of the
membrane repair machinery [40]. Another well-defined example
is that oligomerization of p53 in the MDM2 complex in
association with other molecules (like ATM and BAK) in response
to DNA damage [41,42]. Importantly, distinct from the way of
other molecules forming oligomers, we found that VHL
oligomerization is a result of its SUMO1 rather than its ubiquitin
modification. Moreover, the carboxyl terminus of VHL contains
an oligomerized domain which is similar to the oligomerized
sequence of p53 [43,44], although the native VHL forms much
less oligomers than native p53 by in vitro cross-linking (supple-
mentary information, Figure S2A). The evidence of high-level
oligomerization of the SUMO1-modified VHL (VHL-SUMO
DC4)
in the in vitro cross-linking assay, suggests that VHL has a unique
space structure and requires SUMO modification to alter its
conformation before oligomerization. In addition, as shown in
Figure 3E, the highly conserved sequence of the oligomerization
domain among VHL homologs from different species suggests that
the process of VHL oligomerization may be important for
reversible regulation of VHL function. To our knowledge, this
strategy by which hypoxic stress affects posttranslational modifi-
cation of VHL provides a potentially novel alternative molecular
mechanism for altering the function of critical cellular regulator
under environmental stress.
Lysine residues act as acceptors not only for SUMO
modification but also for all other Ubls (methylation and
acetylation) [22]. It is therefore possible that SUMO conjugation
could block other lysine dependent modification such as
ubiquitylation. Previous studies have shown that VHL can be
Neddylated on lysine 159 to associate with fibronectin matrix
assembly and suppression of tumor development [28,45], however,
this posttranslational modification is not related to its E3 ligase
activity. In our study, we have demonstrated that VHL loses its
ability for HIFa modulation through SUMOylation and
oligomerization through the action of the SUMO E3 ligase
PIASy. The consequences of this modification include: 1)
Conjugation of VHL to SUMO1 which alters protein-protein
interaction with its substrates; and 2) Competition with other
posttranslational modifiers. In support of this, we also demon-
strated that VHL is also ubiquitylated on Lysine 171 in addition
to SUMOylation (data not shown). Thus, SUMO1 modification
can compete with VHL ubiquitylation for the major conjugation
site at Lys171. It was previously shown that similar competition
between SUMOylation and ubiquitylation occurs at the Lys-21
of IkBa [46]. This active interplay between SUMOylation and
ubiquitylation is likely to dictate the degree of VHL stability,
and SUMO1 modification of VHL will have a major impact on
its inactivity as a ubiquitin ligase. However, the potential of
SUMOylation resulting in the inhibition of VHL ubiquitylation
will provide a mechanism which distinguishes between substrate
ubiquitylation and self-ubiquitylation. The identification of
PIASy mediated VHL SUMOylation and instead of ubiquityla-
tion now opens the possibility that PIASy is a component of a
finely balanced regulatory process in response to hypoxic stress.
To our knowledge factors that transmit conflicting signals to
VHL is a rarity. It is therefore tempting to speculate that PIASy
is a key player contributing to transmission and integration of
signals to inactivate VHL-mediated inhibitory functions on both
HIFa and other molecules. The duration of protein SUMOyla-
tion is expected to reflect the time frame during which the
ubiquitylation of VHL occurs. A temporal increase in VHL
SUMOylation occurs in response to hypoxia and is inversely
correlated with elevated levels of HIF1a.T h ef a c tt h a t
attenuated VHL SUMOylation by inhibition of PIASy is likely
to explain why VHL is still capable of mediating the efficient
destruction of HIFa during hypoxia.
Figure 8. A model for the role of PIASy on VHL in response to hypoxic stress. Hypoxia enhances the interaction of PIASy with VHL, and
induces PIASy-mediated VHL SUMOylation and oligomerization, and in turn results in the inactivation of VHL regulation in HIFa-dependent and
independent pathways, which include angiogenesis, cell survival and proliferation, and cell mobility. However, loss of PIASy increases the VHL-
mediated ECV (Elongin BC-Cullin 2/VHL) E3 ubiquitin complex targeting HIFa for ubiquitylation and proteasome-mediated degradation in the
presence or absence of oxygen, and eventually leads to tumor suppression.
doi:10.1371/journal.pone.0009720.g008
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for VHL mRNA [47,48]. The VHL mRNA produces two native
proteins: full length VHL and the shorter VHL19 with the first 53
residues deleted [47,48]. Studies have shown that both proteins are
functionally active and the majority of the disease-associated
mutations are located downstream of the second translational
initiation site [48]. Mutations in the first 53 codons of the VHL
gene have no effect on the structure of the shorter VHL protein.
However, our studies showed that only full length VHL but not
VHL19 significantly interacts with PIASy, suggesting that there are
distinct biological functions between these two isoforms of VHL
and that PIASy association is most likely a critical one.
Interestingly, recent studies have shown that concurrent mutations
in the first 53 codons do contribute to VHL associated diseases
[49], which is significant for the specific interaction of PIASy with
full length VHL in an adaptive response to hypoxia stress.
Materials and Methods
DNA constructs, antibodies and reagents
Plasmids encoding human PIAS protein family (1, 3, x, and y)
with FLAG tag were gifts from Stefan Mu ¨ller (Max Planck
Institute of Biochemistry, Germany), and Ke Shuai (University of
California Los Angeles, USA). PIASyD1-157, PIASyD183-415,
PIASy1-233, PIASy1-415, PIASy1-461, and PIASy1-492 with
FLAG tag were generated by ligating BamHI/EcoRV PCR
fragments into the plasmid of pcDNA-FLAG. PIASy 1-492 with
myc tag were generated by ligating BamHI/EcoRV PCR fragments
into the pA3M vector. GST-PIASy1-492 was generated by ligating
BamHI/EcoRI PCR fragments into the pGEX-2TK vector.
Plasmids HA-VHL and FLAG-VHL were provided individually
by Kaelin WG Jr. (Harvard Medical School) and Joan W
Conaway (Stowers Institute for Medical Research, USA). The
truncated mutants of HA-VHL D1-53, HA-VHL 54-190, HA-
VHL 54-151, HA-VHL 54-120 and HA-Ubc9 were constructed
by ligating BamHI/EcoRI PCR fragments into the plasmid of
pcDNA3HA. Constructs of HA-VHL1-120, HA-VHL1-170, and
HA-VHL1-190 (which derived from wild type HA-VHL by
introducing TGA stop codon as indicated position), FLAG-VHL
(K171R, K196R, or K159R), PIASy
C342/347A-myc and VHL-
SUMO1
DC4 (Mut1 and Mut2) were individually generated by
PCR site-directed mutagenesis. VHL-Ub
DGG and VHL-SU-
MO1
DC4 were generated by in-frame ligation of BamHI/XbaI
PCR fragments to the downstream of FLAG-VHL (K171R). All
constructs were confirmed by direct DNA sequencing. Constructs
of pCEP4/HIF1a and wild type HIF1a target reporter pGL2-
wHRE, pGL2-mHRE, pGL3-1.5VEGFp, and p53-myc were
previously described [50,51]. The VHL antibodies were from Cell
signaling technology Inc. SUMO1 (Y299) antibodies were from
Abcam. HIF1a antibodies were from BD transduction laboratory.
PIASy (I-19) was purchased from Santa Cruz Biotech. Inc. Other
antibodies used were anti-myc (9E10), anti-FLAG (M2), anti-HA
(12CA5), and b-Actin (Cell signaling technology). The deSU-
MOylation inhibitor N-Ethylmaleimide (NEM) was purchased
from Sigma. Proteasome inhibitor MG132 was purchased from
Biomol International.
Cell culture and transfection
Human renal carcinoma VHL-null cell lines 786-O and RCC4
(Kindly provided by Dr Volker H. Haase from University of
Pennsylvania Medical School of Medicine, Philadelphia, PA),
osteosarcoma p53-null cell line Saos-2 (Kindly provided by Dr Jon
Aster from Brigham and Women’s Hospital, Boston, MA), and
embryonic kidney (HEK) 293 cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 5% fetal
bovine serum (FBS, Hyclone), 4 mM L-glutamine, penicillin, and
streptomycin [51]. All cells were incubated at 37uC in a humidified
environmental incubator supplemented with 5% CO2. Ten
million cells with 400 ml medium were transfected by electropo-
ration with a Bio-Rad Gene Pulser in 0.4 cm-gap cuvettes at 210
Volts and 975 microfarads or calcium phosphate transfection [51].
Hypoxic treatment
Cells were cultured at 37uC and 5% CO2 in air to reach less
than 50% confluency before being transferred to an exposure
chamber, which was flushed with 1% O2 balanced with 5% CO2
and 95% N2. The chamber was then sealed airtight and kept at
37uC for the duration of hypoxia treatment [50]. For chemical
hypoxia, cells were exposed to 100 mM Cobalt Chloride (Sigma)
[50].
Immunoprecipitation and Immunoblotting
Immunoprecipitation (IP) and immunoblotting (IB) assays were
performed as described previously [51]. Briefly, cells were
harvested and washed once with ice-cold phosphate-buffered
saline (PBS) and lysed in 1 ml cold radioimmunoprecipitation
assay (RIPA) buffer (50 mM Tris [pH 7.6], 150 mM NaCl, 2 mM
EDTA, 1% Nonidet P-40, 1 mM PMSF, leupeptin [1 mgm l
21],
aprotinin [1 mgm l
21], and pepstatin [1 mgm l
21] with or without
10 mM N-ethylmaleimide (NEM)]) on ice and homogenized. The
supernatant of lysates were pre-cleared with protein A/G
Sepharose beads (Amersham Biosciences, Piscataway, N.J.); and
then incubated with primary antibody 2 h at 4uC with constant
rotation and then with protein A/G Sepharose beads for 1 h.
Beads were washed 5 times with TBS buffer, resuspend in 50 mlo f
16 SDS Laemmli buffer and heated 95uC for 5 minutes. The
sample was subjected to SDS-PAGE and transferred to a
membrane that was probed with specific antibody. For denatured
IP, cells were boiled 10 min at 1% SDS-containing Tris-buffered
saline, followed by sonication and 18-fold dilution with TBS
containing 1% Triton X-100. The cell lysates were immunopre-
cipitated with SUMO1 (Y299) antibody [21].
Protein expression, and in vitro pull-down assay
GST and GST-PIASy were expressed in BL21 (DE3) E.coli cells
and purified as previously described[51]. Briefly, overnight starter
cultures (50 ml) of Escherichia coli BL21 (DE3) transformed with
pGEX-2T-PIASy mutants were incubated into 500 ml of culture
medium and grown at 30uC to an optical density of about 0.6 at
600 nm. After isopropylthiogalactopyranoside (IPTG) induction
(0.5 mM, 2 hrs at 30uC), for GST-fused protein, bacteria were
collected and sonicated in lysis buffer containing 20 mM Tris-HCl
pH 8.0, 100 mM NaCl, 0.5% NP40, 1 mM EDTA, 1 M DTT,
5% Sarkosyl and the protease inhibitor cocktail. For pull-down
assay,
35S-methionine-labeled in vitro-translated proteins were
incubated with the relevant GST-fusion proteins loaded on
glutathione sepharose bead for 4 hrs at 4uC in GST binding
buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 10 mm ZnCl2,
10% glycerol, freshly supplemented with 0.1 mM dithiothreitol
(DTT) and protease inhibitor). After washing, bound proteins were
eluted with SDS sample buffer and analyzed by gel electrophoresis
followed by direct antuoradiography and scan by Phospho Imager
(Amersham Biosciences Inc., Piscataway, NJ).
In vitro SUMOylation assay
In vitro SUMOylation kit was purchased from BostonBiochem
Incorp. (Cambridge, MA). The reaction was carried out at 37uC
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SUMO1 (50 mM), ATP (1 mM), and
35S-methionine-labeled in
vitro-translated wild type FLAG-VHL or its mutants (2 ml) in total
20 ml volume.
Oligomerization assay
In vitro translated, radiolabeled proteins (3 ml) were resuspended
in NETN buffer (20 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.5%
NP40, 1 mM EDTA, and the protease inhibitor cocktail), and
then incubated on ice for 15 min with or without 0.1%
glutaraldehyde[52]. Proteins were then resolved by SDS-PAGE
and analyzed by autoradiography.
Luciferase reporter assay
Luciferase reporter plasmids pGL2-wHRE and pGL2-mHRE
(pGL2, containing 3 tandem repeats of HIF-binding sites or its
mutants) were gifts from Gregg Semenza (Johns Hopkins
University). The luciferase reporter assays were performed as
described previously[51]. After transfection for 48 h, cells were
lysed in 200 ml of reporter lysis buffer (Promega, Inc., Madison,
WI). Luciferase activities and b-galactosidase were individually
measured using luciferase assay reagent (Promega, Inc., Madison,
WI) and the OpticompI Luminometer (MGM Instruments, Inc.
Hamden, CT) according to the suppliers’ instructions. Luciferase
activities were normalized with b-galactosidase activities. Relative
luciferase activity (RLU) was expressed as fold activation relative
to the reporter construct alone. Assays were performed in
triplicate.
RNA interference
For RNA interference with luciferase reporter assays, the PIASy
shRNA sequence (59-GTACTTAAACGGACTGGGA-39), Ubc9
shRNA sequence (59-GGGAAGGAGGCTTGTTTAAAC-39),
and the control sequence (59-TGCGTTGCTAGTACCAAC-39,
non-targeting sequence), were cloned into RNAi-Ready pSIREN
(Clontech). For the Lentivirus-mediated stable knockdown of
PIASy, the PIASy shRNA sequence was inserted into pGIPz
vector according to the manufacturer’s instructions (Clonetech),
293 and 786-O cells were individually transduction by Lentivirus
packaged from Core T which cotransfected with Rev, VSVG and
gp expressing plasmids, and selection by 1 mg/ml Puromycin.
pGIPz vector with luciferase target sequence (shLuc) was used as
control, and the RNA interfering efficiency was assessed by
western blot analysis.
Endothelial tube formation assay
Human umbilical vascular endothelial cells (HUVEC) were
purchased (Cambrex) and maintained in EBM-2 medium
supplemented with EGM-2. Tube formation assay on extracellular
BD matrigel was performed according to the manufacturer’s
protocol with minor modifications. Briefly, 2610
4 HUVEC
resuspended with 500 ml of EBM-2 medium were seeded on
Matrixgel solidified in 48-wel tissue culture plate. Conditioned
medium (1 ml) from the supernatant of each 786-O stable cells
was added, respectively. Cells were incubated in a CO2 incubator
for 24 hrs at 37uC and then examined for tube formation with a
light microscope.
Flow cytometry, cell cycle assay
Cells were transfected with an empty vector, wild type FLAG-
VHL or its mutants in 100-mm dishes. After incubation, cells were
harvested and washed twice with PBS. They were fixed by
treatment with 1 ml of 70% ethanol, gently vortexed and kept at
4uC until used. Fixed cells were washed once with PBS and
resuspend in a propidium iodide solution (10 mgm l
21) containing
RNase A (250 mgm l
21). Propidium iodide-stained cells were then
analyzed for their DNA contents by using a FACSCalibur
cytometer (Becton Dickinson, San Jose, CA) and FlowJo software
(Tree Star, Ashland, OR).
Characterization of cell growth in vitro
Cells transfected with wild type VHL and its mutants were
selected by G418 (1 mg ml
21) and 2610
5 cells were plated into 6-
well plates. Cell numbers were counted with a hemocytometer
(Beckman Coulter) at each time point for 10 days. Cell counts
were performed in triplicate.
Cell migration assay
Cell mobility was assessed using a scratch wound assay. Stably
transfected cells were cultured in 6-well plates until confluent. The
cell layers were carefully wounded using sterile tips and washed
twice with fresh medium. After incubation for 12, 24 and 36 hrs,
the cells were photographed under a phase-contrast microscope.
The experiments were performed in triplicate.
3D multicellular tumor spheroid assay
For multicellular spheroids were prepared as described
previously [29]. Briefly, 48-well tissue culture plates were coated
with 50 ml of prewarmed 0.5% soft agrose in serum-free medium.
A total of 10
4 transfected cells with G418 (1 mg ml
21) selection
were resuspended in 0.5 ml of DMEM supplemented with 10%
fetal calf serum and added to the agrose-coated wells. The cells
were grown in a humidified 5% CO2 atmosphere at 37uC for 3
days. Digital images were taken at 640 magnification.
Supporting Information
Figure S1 The homologous sequence with potential SUMO
modified sites in VHL from different species. AD, acidic domain;
m, mouse; r, rabbit; d, dog, M, monkey; h, homo sapiens.
Found at: doi:10.1371/journal.pone.0009720.s001 (1.46 MB TIF)
Figure S2 (A) Crosslinking assays in vitro. VHL, VHL-
SUMO1dC4 and VHL-UbdGG proteins were individually in
vitro translated, radiolabelled, and treated with different concen-
tration glutaraldehyde (GA) and analyzed by SDS-PAGE and
autoradiography. In vitro translated, radiolabelled p53-myc
protein was used as positive control. (B) The stability analysis of
dimerized VHL-SUMO1dC4 in vitro. The in vitro translated
proteins were individually subjected to treatment as indicated in
the figure, and analyzed by SDS-PAGE and autoradiography.
Found at: doi:10.1371/journal.pone.0009720.s002 (3.44 MB TIF)
Figure S3 Beta domain of VHL binds to PIASy in vitro. The
purified GST-PIASy proteins (4 mg each) were incubated
individually with 12 ml in vitro translated 35S-labeled wild type
HA-VHL and its mutants at 4uC for 4 h. After extensive washing,
the samples were resolved by SDS-PAGE and detected by a
Phosphor Imager. The input of VHL and luciferase (luc) as
negative control are shown.
Found at: doi:10.1371/journal.pone.0009720.s003 (1.81 MB TIF)
Figure S4 (A) Loss of PIASy reduces the stability of VHL-
SUMO1DC4 in hypoxia. 786-O stable cells with PIASy
knockdown or luciferase control were individually transfected
with VHL-SUMO1DC4. At 24 hr posttransfection, cells were
equally divided and treated with 1% O2 for 0, 6, 12 or 24 hours.
The levels of VHL-SUMO1DC4 were detected by immunoblot-
ting with anti-FLAG. (B) Loss of PIASy but not Ubc9 attenuates
Hypoxia Inactivates VHL
PLoS ONE | www.plosone.org 13 March 2010 | Volume 5 | Issue 3 | e9720the transcriptional activity of HIF-responsive reporter. HEK293
cells were transiently transfected with pSIREN expressing small
hairpin against PIASy or Ubc9 in the presence of wild type
(wHRE) or mutation (mHRE) HIF-responsive element-luciferase
reporter. Empty vector was used as control. Data are presented
as means6SD of three independent experiments.
Found at: doi:10.1371/journal.pone.0009720.s004 (2.57 MB
TIF)
Figure S5 (A) Loss of PIASy enhances the effect of VHL positive
but not negative cells on cell cycle under serum starve stress. Cells
were plated and incubated for 18 hrs in either 1% oxygen or 0.1%
serum, and directly analyzed by flow cytometry after staining with
propidium iodide. The relative ratios of G0 phase in each group
were presented by compared to luciferase knockdown (shLuc)
control under normal condition. a, HeLa; b, 293; c, 786-O; d,
RCC4. (B) Loss of PIASy suppresses the cell mobility in normoxia.
The cell mobility of HeLa cells with PIASy stable knockdown or
luciferase control in normoxia were determined by wound
migration assay as described previously.
Found at: doi:10.1371/journal.pone.0009720.s005 (2.34 MB
TIF)
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